

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

09847935

L10 ANSWER 1 OF 9 USPATFULL

ACCESSION NUMBER: 2001:185225 USPATFULL
TITLE: Mucoadhesive granules of carbomer suitable for oral administration of drugs
INVENTOR(S): Dettmar, Peter William, Patrington, United Kingdom
Dickson, Paul Andrew, Hull, United Kingdom
Hampson, Frank Chadwick, Hedon, United Kingdom
Jolliffe, Ian Gordon, Cottingham, United Kingdom
Peers, William, Sproatley, United Kingdom
PATENT ASSIGNEE(S): Reckitt Benckiser Healthcare (UK) Limited, Slough, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6306789	B1	20011023
APPLICATION INFO.:	US 1999-416400		19991012 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-614302, filed on 12 Mar 1996, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1995-5032	19950313
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Webman, Edward J.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	607	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Mucoadhesive granules comprising	

- a) carbomer and/or a salt thereof; and
- b) an inert filler.

The granules preferably further comprise a pharmaceutically active agent suitable for sustained release into the gastrointestinal tract or for targeted delivery to the gastrointestinal mucosa.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 9 USPATFULL

ACCESSION NUMBER: 1998:150500 USPATFULL
TITLE: Products and processes for the treatment of the alimentary canal
INVENTOR(S): Rhodes, John, Cardiff, Wales
Evans, Brian Kenneth, Dinas Powys, Wales
PATENT ASSIGNEE(S): Tillotts Pharma AG, Ziefen, Switzerland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843482		19981201
	WO 9201457		19920206
APPLICATION INFO.:	US 1993-966163		19930121 (7)
	WO 1991-GB1209		19910719
			19930121 PCT 371 date

blessing

19930121 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1990-15988	19900720
	GB 1991-1675	19910125
	GB 1991-3795	19910222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Weddington, Kevin E.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	559	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Complexes of bismuth, e.g. bismuth salts, and polyacrylate, e.g. carbomer, are disclosed which may be incorporated into pharmaceutical compositions for oral, oral delayed-release, and rectal administration. The complexes may be combined with an antibiotic, such as tetracycline, and an antiprotozoal agent, e.g. Metronidazole, for use in the treatment of Helicobacter pylori infection. The treatment of inflammatory bowel disease using bismuth/polyacrylate complexes, or other bismuth preparations, is also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 9 USPATFULL

ACCESSION NUMBER: 97:35942 USPATFULL
TITLE: Controlled release of drugs delivered by sublingual or buccal administration
INVENTOR(S): El-Rashidy, Ragab, Deerfield, IL, United States
Ronsen, Bruce, River Forest, IL, United States
Hassan, Emad E., Sidi Gaber, Egypt
PATENT ASSIGNEE(S): Pentech Pharmaceuticals, Inc., Wheeling, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5624677		19970429
APPLICATION INFO.:	US 1995-489966		19950613 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Spear, James M.		
LEGAL REPRESENTATIVE:	Olson & Hierl, Ltd.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	916		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition providing a relatively slow release of water-soluble drugs, such as apomorphine, for delivery via the sublingual or buccal routes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 9 USPATFULL

ACCESSION NUMBER: 97:7665 USPATFULL
TITLE: Dentinal desensitizing compositions

blessing

09847935

INVENTOR(S): Herms, James K., Jersey City, NJ, United States
Markowitz, Kenneth J., Fanwood, NJ, United States
PATENT ASSIGNEE(S): Block Drug Company Inc., Jersey City, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5597552		19970128
APPLICATION INFO.:	US 1993-167558		19931214 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-811811, filed on 20 Dec 1991, now patented, Pat. No. US 5270031		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rose, Shep K.		
LEGAL REPRESENTATIVE:	Ostrolenk, Faber, Gerb & Soffen, LLP		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	367		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition containing a water soluble or water swellable polyelectrolyte mixed salt in a dentifrice base or other oral compositions which can be used for relieving pain and discomfort caused by hypersensitive teeth.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 5 OF 9 USPATFULL

ACCESSION NUMBER: 96:70482 USPATFULL
TITLE: Denture stabilizing compositions
INVENTOR(S): Rajaiah, Jayanth, Loveland, OH, United States
Saud, Abel, Milford, CT, United States
MacKay, Bruce J., Cincinnati, OH, United States
Grubbs, Dennis R., Atizapan, Mexico
PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5543443		19960806
APPLICATION INFO.:	US 1992-904782		19920803 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-825885, filed on 27 Jan 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Michl, Paul R.		
ASSISTANT EXAMINER:	Asinovsky, Olga		
LEGAL REPRESENTATIVE:	Poland, Mary Catherine, Mohl, Douglas C., Rasser, Jacobus C.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	493		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are denture adhesive compositions possessing improved aesthetics and comprising a component which provides for easy removal of the adhesive from the denture and a hydrophilic powder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 6 OF 9 USPATFULL

blessing

09847935

ACCESSION NUMBER: 95:112347 USPATFULL
TITLE: Deposition of materials to surfaces using zwitterionic carrier particles
INVENTOR(S): Somasundaran, Ponisseril, Nyack, NY, United States
Ananthapadmanabhan, Kavssery P., New Windsor, NY, United States
Fujiwara, Mitsuko, Edgewater, NJ, United States
Tsaur, Liang S., Norwood, NJ, United States
PATENT ASSIGNEE(S): Lever Brothers Company, Division of Conopco, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5476660		19951219
APPLICATION INFO.:	US 1994-285270		19940803 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Gardner, Sally		
LEGAL REPRESENTATIVE:	Mitelman, Rimma		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	951		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions to deposit an active substance on a target surface (i.e. fabric, sun, hair, teeth). The active substance is left on the surface, after the product is rinsed off the surface. The preferred deposition is from compositions containing an anionic or nonionic active in the co-presence of an anionic surfactant. The compositions contain carrier particles having a zwitterionic or cationic surface and a plurality of outwardly protruding filaments containing charged organocarbyl groups. The active substance is contained within the carrier particles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 7 OF 9 USPATFULL

ACCESSION NUMBER: 95:27080 USPATFULL
TITLE: Delayed release oral dosage forms for treatment of intestinal disorders
INVENTOR(S): Rhodes, John, 25 Nantfawr Road, Cyncoed, Cardiff, South Glamorgan CF2 6JO, United Kingdom
Evans, Brian K., 9 Merevale, The Common, Dinas Powis, South Glamorgan CF6 4HS, United Kingdom

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5401512		19950328
	WO 9214452		19920903
APPLICATION INFO.:	US 1993-107744		19930820 (8)
	WO 1992-GB318		19920221
			19930820 PCT 371 date
			19930820 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1991-3795	19910222
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	

blessing

09847935

ASSISTANT EXAMINER: Hulina, Amy
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 608

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An orally administrable pharmaceutical dosage form for selectively administering a drug to the intestine comprises a plurality of enteric coated granules of the drug contained in an enterically coated capsule which releases the granules in the small intestine. The granules are preferably coated with a coating which remains intact until the coated granules reach at least the ileum and thereafter provide a sustained release of the drug in the colon. Suitable coating materials are selected from the Eudragit range of (meth)acrylate and (meth)acrylic and polymers. The invention has particular application to topically active drugs such as topically active steroids, bismuth salts and complexes, and especially, 5-amino-salicylic acid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:696668 CAPLUS
DOCUMENT NUMBER: 127:351219
TITLE: Hydrophobic carbomer complex compositions
INVENTOR(S): Sachetto, Jean-pierre; Buser, Thomas
PATENT ASSIGNEE(S): Tillotts Pharma Ag, Switz.; Sachetto, Jean-Pierre;
Buser, Thomas
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9738726	A2	19971023	WO 1997-EP1847	19970414
WO 9738726	A3	19971231		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2251849	AA	19971023	CA 1997-2251849	19970414
AU 9726965	A1	19971107	AU 1997-26965	19970414
EP 914160	A2	19990512	EP 1997-920670	19970414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2001509781	T2	20010724	JP 1997-536740	19970414
PRIORITY APPLN. INFO.:			GB 1996-7955	A 19960417
			WO 1997-EP1847	W 19970414

AB Hydrophilic carbomer complexes, such as bismuth or nicotine carbomer, are rendered hydrophobic at neutral to acid pH by milling to pass a 150 .mu.m sieve screen and then impregnating with a water-insol. anionic polymer. Preferred anionic polymers are

blessing

09847935

partly Me esterified methacrylic acid polymers. A hydrophobic impregnated powder was prepd. from Bi carbomer, Eudragit S100 and tri-Et citrate.

L10 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:400887 CAPLUS

DOCUMENT NUMBER: 127:80202

TITLE: Secreted enzyme production by fungal pellets in a perfusion bioreactor

AUTHOR(S): Su, Wei Wen; He, Bing Jun

CORPORATE SOURCE: Dep. Biosystems Engineering, Univ. Hawaii, Honolulu, HI, 96822, USA

SOURCE: Journal of Biotechnology (1997), 54(1), 43-52

CODEN: JBITD4; ISSN: 0168-1656

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this study, extracellular enzyme prodn. by fungal pellets cultured in a novel continuous perfusion bioreactor is investigated. Cell retention during perfusion culture is achieved by incorporating an internal settling zone into an external-loop air-lift bioreactor. Prodn. of an extracellular enzyme, acid phosphatase, by the filamentous fungus *Neurospora crassa* was chosen as a model system. In order to control culture morphol. to allow effective long-term perfusion culture, an **anionic polymer** Carbopol (carboxypolymethylene) at 0.1% was added to the culture medium to promote growth in a more dispersed form. The bioreactor has shown a high pellet retention efficiency over a wide range of medium perfusion rates. The fungal pellets were successfully cultivated in the bioreactor for over 30 days. By operating the bioreactor under phosphate limitation, and by a step-wise increase of the perfusion rate from 0.5 to 1 d⁻¹, a steady state phosphatase volumetric productivity of ca. 900 U L⁻¹ d⁻¹ was reached while cell dry wt. was maintained at over 4 g L⁻¹.

blessing

09847935blessing

L21 ANSWER 1 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:65400 USPATFULL
TITLE: Alpha-2-adrenergic agonist/fatty acid compositions
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045524	A1	20030306
APPLICATION INFO.:	US 2002-136263	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-848249, filed on 3 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1113		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising an alpha-2-adrenergic agonist component and a fatty acid component, that enhances the pharmacokinetic disposition of the therapeutic component, are disclosed. The fatty acid component may include linolenic acid and/or other fatty acids. In a one embodiment, the alpha-2-adrenergic agonist component and the fatty acid component form a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 2 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2003:23363 USPATFULL
TITLE: Compositions having enhanced pharmacokinetic characteristics
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003017199	A1	20030123
APPLICATION INFO.:	US 2002-136240	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-847935, filed on 3 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1402		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising a therapeutic component and an efficacy enhancing component, that enhances the pharmacokinetic disposition of the therapeutic component, are disclosed. The therapeutic component may include an alpha-2-adrenergic agonist and the efficacy enhancing component may include fatty acids. In one embodiment, the therapeutic component and the efficacy enhancing component form a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 3 OF 6 USPATFULL on STN

09847935blessing

ACCESSION NUMBER: 2002:344479 USPATFULL
TITLE: ALPHA-2-ADRENERGIC AGONIST/FATTY ACID COMPOSITIONS
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales Inc., Irvine, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198210	A1	20021226
APPLICATION INFO.:	US 2001-848249	A1	20010503 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	774		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Alpha-2-Adrenergic Agonist/Fatty Acid Compositions Compositions comprising an alpha-2-adrenergic agonist component and a fatty acid component are disclosed. In one embodiment, the fatty acid components include fatty acids. In a preferred embodiment, the alpha-2-adrenergic agonist component and the fatty acid component forms a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 4 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:344478 USPATFULL
TITLE: Compositions having enhanced pharmacokinetic characteristics
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales Inc., Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198209	A1	20021226
APPLICATION INFO.:	US 2001-847935	A1	20010503 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1065		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising a therapeutic component and an efficacy enhancing component that enhances the pharmacokinetic disposition of the therapeutic component is disclosed. In one embodiment, the therapeutic component includes an alpha-2-adrenergic agonist. In another embodiment, the efficacy enhancing components include fatty acids. In a preferred embodiment, the therapeutic component and the efficacy enhancing component forms a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 5 OF 6 USPATFULL on STN

ACCESSION NUMBER: 2002:17328 USPATFULL
TITLE: Dha-pharmaceutical agent conjugates of taxanes

09847935blessing

INVENTOR(S): Shashoua, Victor, Brookline, MA, UNITED STATES
Swindell, Charles, Merion, PA, UNITED STATES
Webb, Nigel, Bryn Mawr, PA, UNITED STATES
Bradley, Matthews, Layton, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002010208	A1	20020124
	US 6602902	B2	20030805
APPLICATION INFO.:	US 2001-846838	A1	20010501 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-135291, filed on 17 Aug 1998, ABANDONED Continuation of Ser. No. US 1996-651312, filed on 22 May 1996, GRANTED, Pat. No. US 5795909		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Esq., Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2437		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 6 OF 6 USPATFULL on STN

ACCESSION NUMBER: 1998:98932 USPATFULL
TITLE: DHA-pharmaceutical agent conjugates of taxanes
INVENTOR(S): Shashoua, Victor E., Brookline, MA, United States
Swindell, Charles S., Merion, PA, United States
Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
PATENT ASSIGNEE(S): Neuromedica, Inc., Conshohocken, PA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5795909		19980818
APPLICATION INFO.:	US 1996-651312		19960522 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	27 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	2451		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

09847935blessing

09847935blessing

L20 ANSWER 1 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:258442 USPATFULL
TITLE: Therapeutic methods employing disulfide derivatives of
dithiocarbamates and compositions useful therefor
INVENTOR(S): Lai, Ching-San, Carlsbad, CA, UNITED STATES
Vassilev, Vassil P., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Medinox, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181495	A1	20030925
APPLICATION INFO.:	US 2003-394794	A1	20030321 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-44096, filed on 11 Jan 2002, GRANTED, Pat. No. US 6596770 Division of Ser. No. US 2000-565665, filed on 5 May 2000, GRANTED, Pat. No. US 6589991 Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, GRANTED, Pat. No. US 6093743		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Page(s)		
LINE COUNT:	2591		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel combinations of dithiocarbamate
disulfide dimers with other active agents. In one method, the disulfide
derivative of a dithiocarbamate is coadministered with a
thiazolidinedione for the treatment of diabetes. In another embodiment,
In another embodiment, invention combinations further comprise
additional active agents such as, for example, metformin, insulin,
sulfonylureas, and the like. In another embodiment, the present
invention relates to compositions and formulations useful in such
therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 2 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:127625 USPATFULL
TITLE: Conjugates of dithiocarbamates with pharmacologically
active agents and uses therefor
INVENTOR(S): Lai, Ching-San, Carlsbad, CA, UNITED STATES
Wang, Tingmin, San Marcos, CA, UNITED STATES
PATENT ASSIGNEE(S): Medinox, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003087840	A1	20030508
APPLICATION INFO.:	US 2002-176396	A1	20020618 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-453608, filed on 3 Dec 1999, GRANTED, Pat. No. US 6407135 Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278		

09847935blessing

NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 2139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 3 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:85867 USPATFULL
TITLE: Oral delivery formulation
INVENTOR(S): Compton, Bruce Jon, Lexington, MA, UNITED STATES
Solari, Nancy E., West Newton, MA, UNITED STATES
Flangan, Margaret A., Stow, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003059471	A1	20030327
APPLICATION INFO.:	US 2001-997277	A1	20011129 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-55560, filed on 6 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-69501P	19971215 (60)
	US 1998-73867P	19980204 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Stephen J Gaudet, 68H Stiles Road, Salem, NH, 03079	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2950	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flakes containing drugs and methods for forming and using such flakes are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 4 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:65400 USPATFULL
TITLE: Alpha-2-adrenergic agonist/fatty acid compositions
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003045524 A1 20030306
APPLICATION INFO.: US 2002-136263 A1 20020501 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-848249, filed
on 3 May 2001, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite
300, 4 Venture, Irvine, CA, 92618
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
LINE COUNT: 1113

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising an alpha-2-adrenergic agonist component and a
fatty acid component, that enhances the pharmacokinetic disposition of
the therapeutic component, are disclosed. The fatty acid component may
include **linolenic acid** and/or other fatty acids. In
a one embodiment, the alpha-2-adrenergic agonist component and the fatty
acid component form a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 5 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:23363 USPATFULL
TITLE: Compositions having enhanced pharmacokinetic
characteristics
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003017199	A1	20030123
APPLICATION INFO.:	US 2002-136240	A1	20020501 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-847935, filed on 3 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1402		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising a therapeutic component and an efficacy
enhancing component, that enhances the pharmacokinetic disposition of
the therapeutic component, are disclosed. The therapeutic component may
include an alpha-2-adrenergic agonist and the efficacy enhancing
component may include fatty acids. In one embodiment, the therapeutic
component and the efficacy enhancing component form a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 6 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2003:184100 USPATFULL
TITLE: Therapeutic methods employing disulfide derivatives of
dithiocarbamates and compositions useful therefor
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6589991	B1	20030708
APPLICATION INFO.:	US 2000-565665		20000505 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E., Foley & Lardner		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2498		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2002:868738 CAPLUS

DOCUMENT NUMBER: 137:358162

TITLE: Alpha-2-adrenergic agonist/fatty acid compositions

INVENTOR(S): Woodward, David F.; Ambrus, Gyorgy

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002089804	A1	20021114	WO 2002-US12219	20020417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002198210	A1	20021226	US 2001-848249	20010503
PRIORITY APPLN. INFO.: US 2001-848249 A 20010503				

09847935blessing

AB Compns. comprising an .alpha.2-adrenergic agonist component and a fatty acid component are described. In a preferred embodiment, the .alpha.2-adrenergic agonist component and the fatty acid component form a complex, such as an ion pair complex. For example, brimonidine-linoleic acid ion pair complex was able to reduce intraocular pressure in a rabbit's eye for at least 6 h.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 8 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:344479 USPATFULL
TITLE: ALPHA-2-ADRENERGIC AGONIST/FATTY ACID COMPOSITIONS
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales Inc., Irvine, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198210	A1	20021226
APPLICATION INFO.:	US 2001-848249	A1	20010503 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
LINE COUNT:	774		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Alpha-2-Adrenergic Agonist/Fatty Acid Compositions Compositions comprising an alpha-2-adrenergic agonist component and a fatty acid component are disclosed. In one embodiment, the fatty acid components include fatty acids. In a preferred embodiment, the alpha-2-adrenergic agonist component and the fatty acid component forms a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 9 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:344478 USPATFULL
TITLE: Compositions having enhanced pharmacokinetic characteristics
INVENTOR(S): Woodward, David F., Lake Forest, CA, UNITED STATES
Ambrus, Gyorgy, Santa Ana, CA, UNITED STATES
PATENT ASSIGNEE(S): Allergan Sales Inc., Irvine, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198209	A1	20021226
APPLICATION INFO.:	US 2001-847935	A1	20010503 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Frank J. Uxa, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1065		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions comprising a therapeutic component and an efficacy enhancing component that enhances the pharmacokinetic disposition of the therapeutic component is disclosed. In one embodiment, the therapeutic

component includes an alpha-2-adrenergic agonist. In another embodiment, the efficacy enhancing components include fatty acids. In a preferred embodiment, the therapeutic component and the efficacy enhancing component forms a complex.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 10 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:273412 USPATFULL

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

INVENTOR(S): Lai, Ching-San, Encinitas, CA, UNITED STATES
Vassilev, Vassil, San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): Medinox, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151540	A1	20021017
	US 6596770	B2	20030722
APPLICATION INFO.:	US 2002-44096	A1	20020111 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-565665, filed on 5 May 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Stephen E. Reiter, Foley & Lardner, P.O. Box 80278, San Diego, CA, 92138-0278		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Page(s)		
LINE COUNT:	2548		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 11 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:85531 USPATFULL

TITLE: POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING
MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND
DIAGNOSTIC APPLICATIONS

INVENTOR(S): LAI, CHING-SAN, ENCINITAS, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045573	A1	20020418
APPLICATION INFO.:	US 1999-409645	A1	19991001 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-899087, filed on 23 Jul 1997, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-25867P	19960910 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN E REITER, GRAY WARE & FREIDENRICH LLP, 4365 EXECUTIVE DRIVE SUITE 1600, SAN DIEGO, CA, 921212189	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	1763	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there is provided a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. Thus, in accordance with the present invention, dithiocarbamates are linked to the surface of a non-immunogenic, non-targeting macromolecule other than an antibody (e.g., albumin protein) either by using cross-linking reagents or by nonspecific binding to produce polydithiocarbamate-macromolecule-containing compositions, which represent a new class of drugs for therapeutic treatment of such indications as cerebral stroke and other ischemia/reperfusion injury. In accordance with another aspect of the present invention, combinational therapeutic methods have been developed for the in vivo inactivation or inhibition of formation (either directly or indirectly) of species which induce the expression of inducible nitric oxide synthase, as well as reducing nitric oxide levels produced as a result of .NO synthase expression. In accordance with yet another aspect of the present invention, magnetic resonance imaging methods have been developed for the measurement of cerebral and cardiac blood flow and infarct volume in ischemic stroke or heart attack situations. Such methods employ iron-containing complexes of a composition comprising a dithiocarbamate and a non-immunogenic, non-targeting macromolecule other than an antibody as contrast agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 12 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2002:144299 USPATFULL

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor

INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Wang, Tingmin, San Marcos, CA, United States

PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6407135	B1	20020618
APPLICATION INFO.:	US 1999-453608		19991203 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US10295, filed on 19 May 1998 Continuation of Ser. No. US 1997-869158, filed on 4 Jun 1997, now patented, Pat. No. US 5916910		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Davenport, Avis M.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E., Foley & Lardner		
NUMBER OF CLAIMS:	21		

09847935blessing

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 2157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 13 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2001:90260 USPATFULL
TITLE: Fatty acid-pharmaceutical agent conjugates
INVENTOR(S): Webb, Nigel L., Bryn Mawr, PA, United States
Bradley, Matthews O., Laytonsville, MD, United States
Swindell, Charles S., Merion, PA, United States
Shashoua, Victor E., Brookline, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001002404	A1	20010531
	US 6576636	B2	20030610
APPLICATION INFO.:	US 2000-730450	A1	20001205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-651428, filed on 22 May 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Edward R. Gates, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	14 Drawing Page(s)		
LINE COUNT:	2511		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 14 OF 17 USPATFULL on STN
ACCESSION NUMBER: 2001:202682 USPATFULL
TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbonates and compositions useful therefor
INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States
PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316502	B1	20011113
APPLICATION INFO.:	US 2000-565666		20000505 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-103639, filed on 23 Jun 1998, now patented, Pat. No. US 6093743		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E.Foley & Lardner		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2591		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 15 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2001:131342 USPATFULL
 TITLE: Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor
 INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
 Vassilev, Vassil P., San Diego, CA, United States
 Wang, Tingmin, San Marcos, CA, United States
 PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274627	B1	20010814
APPLICATION INFO.:	US 1999-416619		19991012 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Reiter, Stephen E.Foley & Lardner		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2173		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of physiologically compatible free radical scavengers (e.g., dithiocarbamate disulfides (DD)) and pharmacologically active agents

(e.g., NSAIDS). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of free radical overproduction induced thereby as a result of the co-production of free radical scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT. . ,

L20 ANSWER 16 OF 17 USPATFULL on STN

ACCESSION NUMBER: 2000:95042 USPATFULL

TITLE: Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor

INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States
Vassilev, Vassil, San Diego, CA, United States

PATENT ASSIGNEE(S): Medinox Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6093743		20000725
APPLICATION INFO.:	US 1998-103639		19980623 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Weddington, Kevin E.		
LEGAL REPRESENTATIVE:	Gary Cary Ware & Freidenrich, Reiter, Stephen E., Kirschenbaum, Shelia R.		
NUMBER OF CLAIMS:	51		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2691		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel dithiocarbamate disulfide dimer useful in various therapeutic treatments, either alone or in combination with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with an agent that inactivates (or inhibits the production of) species that induce the expression of nitric oxide synthase to reduce the production of such species, while, at the same time reducing nitric oxide levels in the subject. In another embodiment, free iron ion levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate(s) to scavenge free iron ions, for example, in subjects undergoing anthracycline chemotherapy. In another embodiment, cyanide levels are reduced in a subject by administration of a disulfide derivative of a dithiocarbamate so as to bind cyanide in the subject. In a further aspect, the present invention relates to compositions and formulations useful in such therapeutic methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 17 OF 17 USPATFULL on STN

ACCESSION NUMBER: 1999:72602 USPATFULL

TITLE: Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore

INVENTOR(S): Lai, Ching-San, Encinitas, CA, United States

09847935blessing

PATENT ASSIGNEE(S): Medinox, Inc., San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5916910		19990629
APPLICATION INFO.:	US 1997-869158		19970604 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Davis, Zinna Northington		
LEGAL REPRESENTATIVE:	Reiter, Esq., Stephen E.Gray, Cary, Ware & Freidenrich		
NUMBER OF CLAIMS:	27		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1842		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In accordance with the present invention, there are provided conjugates of nitric oxide scavengers (e.g., dithiocarbamates, or "DC") and pharmacologically active agents (e.g., NSAIDs). Invention conjugates provide a new class of pharmacologically active agents (e.g., anti-inflammatory agents) which cause a much lower incidence of side-effects due to the protective effects imparted by modifying the pharmacologically active agents as described herein. In addition, invention conjugates are more effective than unmodified pharmacologically active agents because cells and tissues contacted by the pharmacologically active agent(s) are protected from the potentially damaging effects of nitric oxide overproduction induced thereby as a result of the co-production of nitric oxide scavenger (e.g., dithiocarbamate), in addition to free pharmacologically active agent, when invention conjugate is cleaved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

et	Items	Description
S1	6382	ION PAIR OR ION(A) PAIR
S2	0	\$30QUINOXALINE
S3	0	?30QUINOXALINE
S4	28556	QUINOXALINE
S5	618184	FATTY(N)ACID
S6	0	S1 AND S4 AND S5
S7	2	S1 AND S4
S8	1234	S4 AND S5
S9	163958	LINOLEIC OR LINOLENIC OR DECOSAHEXANOIC OR EICOSANOID OR - EICOSANOIDS
S10	650	S8 AND COMPLEX
S11	21	S10 AND S9
S12	21	RD (unique items)
S13	21	RD (unique items)
S14	585808	ANTIBACTERIAL OR BETA-LACTAM OR CEFOTAXIME OR FORMAMIDOPYLTH- IENAMYCIN OR THIENAMYCIN OR NEOMYCIN OR KANAMYCIN OR TETRACYC- LINE
S15	265281	CHLORAMPHENICOL OR CARBENICILLIN OR COLISTIN OR PENICILLIN- ((1W)G OR AMIKACIN OR GENTAMYCIN OR BACTRACIN OR VANCOMYCIN
S16	556891	CROMOLYN OR CORTISONE OR HYDROCORTISONE OR BETAMETHASONE OR DEXAMETHASONE OR PREDNISONE
?s s14 and complex and s9		
	585808	S14
	3770968	COMPLEX
	163958	S9
S17	1460	S14 AND COMPLEX AND S9
?s s15 and complex and s9		
	265281	S15
	3770968	COMPLEX
	163958	S9
S18	837	S15 AND COMPLEX AND S9
?s s16 and complex and s9		
	556891	S16
	3770968	COMPLEX
	163958	S9
S19	1108	S16 AND COMPLEX AND S9
?s s19 and s1		
	1108	S19
	6382	S1
S20	0	S19 AND S1
?s s19 and ion-pair		
	1108	S19
	3149	ION-PAIR
S21	0	S19 AND ION-PAIR
?s s4 and (s19 or s18 or s17)		
	28556	S4
	1108	S19
	837	S18
	1460	S17
S22	29	S4 AND (S19 OR S18 OR S17)

12/8/12 (Item 10 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00277245

PROCESS FOR PRODUCTION OF HIGH PURITY *FATTY* *ACID* SALT PRODUCTS
PROCEDE DE PRODUCTION DE PRODUITS A BASE DE SELS D'ACIDE GRAS TRES PURS
Main International Patent Class: C07C-051/00
Publication Language: English
Fulltext Availability:
 Detailed Description
 Claims
Fulltext Word Count: 4974

12/8/13 (Item 11 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00277244

PRODUCTION OF HIGH PURITY *FATTY* *ACID* SALT PRODUCTS
PREPARATION DE PRODUITS A BASE DE SELS D'ACIDE GRAS TRES PURS
Main International Patent Class: C07C-051/00
Publication Language: English
Fulltext Availability:
 Detailed Description
 Claims
Fulltext Word Count: 3755

12/8/14 (Item 12 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00275530

FOAM CELL DRUG DELIVERY
ADMINISTRATION DE MEDICAMENTS PAR LE BIAIS DE CELLULES SPUMEUSES
Main International Patent Class: A61K-009/50
International Patent Class: A61K-09:127
Publication Language: English
Fulltext Availability:
 Detailed Description
 Claims
Fulltext Word Count: 10149

12/8/15 (Item 13 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00265446

HIGH PURITY *FATTY* *ACID* SALT PRODUCTS
PRODUITS DE SEL D'ACIDE GRAS DE GRANDE PURETE
Main International Patent Class: C07C-051/00
Publication Language: English
Fulltext Availability:
 Detailed Description
 Claims
Fulltext Word Count: 3375

12/8/16 (Item 14 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00244382

DEODORIZED *FATTY* *ACID* SALT FEED SUPPLEMENT
SEL D'ACIDES GRAS DESODORISE CONSTITUANT UN COMPLEMENT NUTRITIONNEL
Main International Patent Class: A23K-001/00
Publication Language: English
Fulltext Availability:
 Detailed Description
 Claims
Fulltext Word Count: 3954

12/8/17 (Item 1 from file: 652)

DIALOG(R)File 652:(c) format only 2001 The Dialog Corp. All rts. reserv.

01030074

ELECTROMOLECULAR PROPULSION IN DIVERSE SEMICONDUCTIVE MEDIA

[EXCITATION, MOBILIZERS, INITIATORS]

U.S. CLASS: 204-456 cross ref: 204-468; 204-546; 436-66; 436-86; 436-88;
436-177; 436-516; 436-806

INTL CLASS: [2] G01N 27-26

FULL TEXT: 3005 lines

12/8/18 (Item 2 from file: 652)

DIALOG(R)File 652:(c) format only 2001 The Dialog Corp. All rts. reserv.

01027674

POLYSACCHARIDE-CONTAINING ADSORBENT

[FOR HEAVY METAL IONS]

U.S. CLASS: 502-402 cross ref: 502-404

INTL CLASS: [2] C02B 1-46; C02B 1-52

FULL TEXT: 838 lines

12/8/19 (Item 3 from file: 652)

DIALOG(R)File 652:(c) format only 2001 The Dialog Corp. All rts. reserv.

01022739

BENZO-[C]-CINNOLINIUM DYESTUFFS

[CATIONIC DYES]

U.S. CLASS: 544-234 cross ref: 544-115

INTL CLASS: [2] C07D 237-36; C07D 401-02; C07D 413-02

FULL TEXT: 2828 lines

12/8/20 (Item 1 from file: 653)

DIALOG(R)File 653:(c) format only 2001 The Dialog Corp. All rts. reserv.

01672379

HEAT DEVELOPABLE LIGHT-SENSITIVE MATERIAL CONTAINING POLYMETHINE

U.S. CLASS: 430-617 cross ref: 430-353; 430-576

INTL CLASS: [4] G03C 1-12

FULL TEXT: 1942 lines

12/8/21 (Item 1 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02748173

2,9-DIAMINO- AND 2-AMINO-8-CARBAMOYL-4-HYDROXY-ALKANOIC ACID AMIDE
DERIVATIVES

[Hypotensive agents]

U.S. CLASS: 514-211 cross ref: 514-213; 514-221; 514-224.2; 514-230.5;
514-249; 514-259; 514-311; 514-315; 514-349; 540-593; 544-52;
544-105; 544-253; 544-283; 544-355; 546-168; 546-175; 546-245;
546-246; 548-309.4; 548-309.7; 548-491; 548-493

INTL CLASS: [6] A61K 31-54; A61K 31-535; C07D 413-02; C07D 411-02

FULL TEXT: 8310 lines

?

12/8/1 (Item 1 from file: 348)

01141332

A thermally developable material

Warmentwickelbares Material

Materiau developpable a la chaleur

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS A	(English)	200017	317
----------	-----------	--------	-----

SPEC A	(English)	200017	12747
--------	-----------	--------	-------

Total word count - document A	13064
-------------------------------	-------

Total word count - document B	0
-------------------------------	---

Total word count - documents A + B	13064
------------------------------------	-------

12/8/2 (Item 2 from file: 348)

00483601

Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom.

Latente Katalysatoren, Hartungsinhibierte Epoxyharze und daraus hergestellte Lamine.

Catalyseurs latents, resines epoxy a durcissement inhibe et stratifie ainsi obtenues.

LANGUAGE (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
----------------	----------	--------	------------

CLAIMS A	(English)	EPABF1	990
----------	-----------	--------	-----

SPEC A	(English)	EPABF1	16658
--------	-----------	--------	-------

Total word count - document A	17648
-------------------------------	-------

Total word count - document B	0
-------------------------------	---

Total word count - documents A + B	17648
------------------------------------	-------

12/8/3 (Item 1 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00798442

THERAPEUTIC COMPOSITIONS INCLUDING PROTEIN KINASE C INHIBITORS

COMPOSITIONS THERAPEUTIQUES COMPRENANT DES INHIBITEURS DE LA PROTEINE KINASE C

Main International Patent Class: A61K-031/00

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 11640

12/8/4 (Item 2 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00774939

LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE

LIAISON D'AGENTS A DES TISSUS PAR LYSINE OXYDASE

Main International Patent Class: A61K-007/48

International Patent Class: A61K-047/48

Publication Language: English

Filing Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 37017

12/8/5 (Item 3 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00774894

LINKAGE OF AGENTS TO TISSU
LIAISON D'AGENTS AVEC UN TISSU
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 34660

12/8/6 (Item 4 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00755934
FATTY *ACID* -N-SUBSTITUTED INDOL-3-GLYOXYL-AMIDE COMPOSITIONS AND USES
THEREOF
COMPOSITIONS D'ACIDES GRAS -N-SUBSTITUTED INDOL-3-GLYOXYL-AMIDE ET LEUR
UTILISATION
Main International Patent Class: A61K-047/48
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 14139

12/8/7 (Item 5 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00740146 **Image available**
FATTY *ACID*-ANTICANCER CONJUGATES AND USES THEREOF
CONJUGUES D'ACIDES GRAS ET D'AGENTS ANTICANCEREUX, ET UTILISATIONS
CORRESPONDANTES
Main International Patent Class: A61K-047/48
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 20899

12/8/8 (Item 6 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00553425
USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS
UTILISATION DE COMPOSES NON-PEPTIDYLIQUES POUR LE TRAITEMENT D'AFFECTIONS
LIEES A L'INSULINE
Main International Patent Class: A61K-038/28
International Patent Class: A61K-031/19; A61K-031/35
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 30998

12/8/9 (Item 7 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00532631
MULTIBINDING AGENTS THAT MODULATE PPARgamma AND RXR RECEPTORS
AGENTS A LIAISONS MULTIPLES MODULANT LES RECEPTEURS PPARgamma ET RXR
Main International Patent Class: A61K-031/095
International Patent Class: A61K-031/135; A61K-031/28; A61K-031/44;
A61K-038/00; A61K-039/00; A61K-039/44; A61K-039/395; A61K-051/00;
C07K-002/00; C07K-004/00; G01N-033/53; G01N-033/543; G01N-033/566

Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 46640

12/8/10 (Item 8 from file: 349)
DIALOG(R) File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00524293
AGRICULTURAL ADJUVANT
ADJUVANT AGRICOLE
Main International Patent Class: C05F-011/00
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 7776

12/8/11 (Item 9 from file: 349)
DIALOG(R) File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00499338
ORAL DELIVERY FORMULATION
FORMULATION D'ADMINISTRATION PAR VOIE ORALE
Main International Patent Class: A61K-009/16
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 26536
?

23/8/1 (Item 1 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00774939
LYSINE OXIDASE LINKAGE OF AGENTS TO TISSUE
LIAISON D'AGENTS A DES TISSUS PAR LYSINE OXYDASE
Main International Patent Class: A61K-007/48
International Patent Class: A61K-047/48
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 37017

23/8/2 (Item 2 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00774894
LINKAGE OF AGENTS TO TISSUE
LIAISON D'AGENTS AVEC UN TISSU
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 34660

23/8/3 (Item 3 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00755934
FATTY ACID-N-SUBSTITUTED INDOL-3-GLYOXYL-AMIDE COMPOSITIONS AND USES THEREOF
COMPOSITIONS D'ACIDES GRAS -N-SUBSTITUTED INDOL-3-GLYOXYL-AMIDE ET LEUR UTILISATION
Main International Patent Class: A61K-047/48
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 14139

23/8/4 (Item 4 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00740146 **Image available**
FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF
CONJUGUES D'ACIDES GRAS ET D'AGENTS ANTICANCEREUX, ET UTILISATIONS CORRESPONDANTES
Main International Patent Class: A61K-047/48
Publication Language: English
Filing Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 20899

23/8/5 (Item 5 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00553425
USE OF NON-PEPTIDYL COMPOUNDS FOR THE TREATMENT OF INSULIN RELATED AILMENTS
UTILISATION DE COMPOSES NON-PEPTIDYLIQUES POUR LE TRAITEMENT D'AFFECTIONS

LIEES A L'INSULINE

Main International Patent Class: A61K-038/28
International Patent Class: A61K-031/19; A61K-031/35
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 30998

23/8/6 (Item 6 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00535566

THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR

METHODES THERAPEUTIQUES UTILISANT DES DERIVES DE BISULFURE DE DITHIOCARBAMATES ET COMPOSITIONS UTILISEES

Main International Patent Class: A61K-031/105
Publication Language: English.
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 26138

23/8/7 (Item 7 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00509555

METHODS FOR THE CONTROLLED DELIVERY OF CARBON DISULFIDE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS

PROCEDES D'APPORT REGULE DE DISULFURE DE CARBONE DANS LE TRAITEMENT D'ETATS INFLAMMATOIRES

Main International Patent Class: A61K-031/13
International Patent Class: A61K-031/40; A61K-031/195
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 14349

23/8/8 (Item 8 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00509435

MODIFIED PHARMACOLOGICALLY ACTIVE AGENTS AND IMPROVED THERAPEUTIC METHODS EMPLOYING SAME

AGENTS MODIFIES, ACTIFS SUR LE PLAN PHARMACOLOGIQUE, ET PROCEDES THERAPEUTIQUES AMELIORES ET METTANT EN OEUVRE CES AGENTS

Main International Patent Class: A01N-037/10
International Patent Class: C07C
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 11020

23/8/9 (Item 9 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00499338

ORAL DELIVERY FORMULATION

FORMULATION D'ADMINISTRATION PAR VOIE ORALE

Main International Patent Class: A61K-009/16
Publication Language: English
Fulltext Availability:

Detailed Description
Claims
Fulltext Word Count: 26536

23/8/10 (Item 10 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00464988
CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND
USES THEREFOR
CONJUGUES DE DITHIOCARBAMATES COMPRENANT DES AGENTS PHARMACOLOGIQUEMENT
ACTIFS ET UTILISATIONS DESDITS CONJUGUES
Main International Patent Class: C07C
International Patent Class: C07C; C07C; C07D; C07D; A61K-31:27; A61K-31:40
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 13806

23/8/11 (Item 11 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00420605
POLYDITHIOCARBAMATE-CONTAINING MACROMOLECULES AND THE USE THEREOF FOR
THERAPEUTIC AND DIAGNOSTIC APPLICATIONS
MACROMOLECULES CONTENANT DU POLYDITHIOCARBAMATE, ET LEUR UTILISATION DANS
DES APPLICATIONS THERAPEUTIQUES ET DIAGNOSTIQUES
Main International Patent Class: C07C
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 15086

23/8/12 (Item 12 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00378062
COMBINATIONAL THERAPEUTIC METHODS EMPLOYING NITRIC OXIDE SCAVENGERS
METHODES THERAPEUTIQUES COMBINEES EMPLOYANT DES ENTRAINEURS DE MONOXYDE
D'AZOTE
Main International Patent Class: A61K-031/325
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 15120

23/8/13 (Item 13 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00277245
PROCESS FOR PRODUCTION OF HIGH PURITY FATTY ACID SALT PRODUCTS
PROCEDE DE PRODUCTION DE PRODUITS A BASE DE SELS D'ACIDE GRAS TRES PURS
Main International Patent Class: C07C-051/00
Publication Language: English
Fulltext Availability:
Detailed Description
Claims
Fulltext Word Count: 4974

23/8/14 (Item 14 from file: 349)
DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00277244

PRODUCTION OF HIGH PURITY FATTY ACID SALT PRODUCTS

PREPARATION DE PRODUITS A BASE DE SELS D'ACIDE GRAS TRES PURS

Main International Patent Class: C07C-051/00

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 3755

23/8/15 (Item 15 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00275530

FOAM CELL DRUG DELIVERY

ADMINISTRATION DE MEDICAMENTS PAR LE BIAIS DE CELLULES SPUMEUSES

Main International Patent Class: A61K-009/50

International Patent Class: A61K-09:127

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 10149

23/8/16 (Item 16 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00265446

HIGH PURITY FATTY ACID SALT PRODUCTS

PRODUITS DE SEL D'ACIDE GRAS DE GRANDE PURETE

Main International Patent Class: C07C-051/00

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 3375

23/8/17 (Item 17 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00250898

COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY

**COMPOSITIONS ET PROCEDES DESTINES A AMELIORER LA LIBERATION ET
L'ACHEMINEMENT DE MEDICAMENTS**

Main International Patent Class: A61K-009/70

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 44687

23/8/18 (Item 18 from file: 349)

DIALOG(R)File 349:(c) 2001 WIPO/Univentio. All rts. reserv.

00244382

DEODORIZED FATTY ACID SALT FEED SUPPLEMENT

SEL D'ACIDES GRAS DESODORISE CONSTITUANT UN COMPLEMENT NUTRITIONNEL

Main International Patent Class: A23K-001/00

Publication Language: English

Fulltext Availability:

Detailed Description

Claims

Fulltext Word Count: 3954

23/8/19 (Item 1 from file: 653)

DIALOG(R)File 653:(c) format only 2001 The Dialog Corp. All rts. reserv.

01474736

PENETRATING TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING

1-DODECYL-AZACYCLOHEPTAN-2-ONE

[ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE]

U.S. CLASS: 514-159 cross ref: 424-449; 424-601; 514-165; 514-223.5;

514-224.2; 514-224.5; 514-226.8; 514-231.2; 514-233.2;

514-236.2; 514-270; 514-374; 514-399; 514-635; 514-947

INTL CLASS: [4] A01N 59-26; A61K 33-42

FULL TEXT: 2319 lines

23/8/20 (Item 2 from file: 653)

DIALOG(R)File 653:(c) format only 2001 The Dialog Corp. All rts. reserv.

01453089

PENETRATING TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING

N-(2-HYDROXYETHYL) PYRROLIDONE

[PERCUTANEOUS DELIVERY OF ANTIINFLAMMATORY AGENTS]

U.S. CLASS: 514-424 cross ref: 514-171; 514-300; 514-549; 514-825; 514-826

; 514-859

INTL CLASS: [3] A01N 43-36; A61K 31-40

FULL TEXT: 2035 lines

23/8/21 (Item 1 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

03357960

CONJUGATES OF DITHIOCARBAMATE DISULFIDES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND USES THEREFOR

U.S. CLASS: 514-599 cross ref: 514-706; 514-707

INTL CLASS: [7] A61K 31-16; A61K 31-095; A61K 31-105

FULL TEXT: 1997 lines

23/8/22 (Item 2 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

03158427

THERAPEUTIC METHODS EMPLOYING DISULFIDE DERIVATIVES OF DITHIOCARBAMATES AND COMPOSITIONS USEFUL THEREFOR

U.S. CLASS: 514-599 cross ref: 514-706; 514-707; 514-851; 514-861; 514-863

; 514-866; 514-909; 514-912

INTL CLASS: [7] A61K 31-16; A61K 31-095; A61K 31-105

FULL TEXT: 2427 lines

23/8/23 (Item 3 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

03042684

TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS

[Administering 5-methyl-isoxazole-4-carboxylic acid-N-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-N-(4-trifluoro-methyl)phenyl-2-butenamide; antitumor,-carcinogenic and proliferative agents; kinase inhibitors]

U.S. CLASS: 514-378 cross ref: 514-521

INTL CLASS: [6] A61K 31-42; A61K 31-275

FULL TEXT: 4359 lines

23/8/24 (Item 4 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

03008970

TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS
CANCERS

[Administering 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-butenamide]

U.S. CLASS: 514-378 cross ref: 514-379; 514-380

INTL CLASS: [6] A61K 31-42

FULL TEXT: 4342 lines

23/8/25 (Item 5 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02980618

TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS
CANCERS

[Antigrowth agents; antitumor agent; using an isooxidazole compound]

U.S. CLASS: 514-380 cross ref: 514-378; 514-379; 514-521

INTL CLASS: [6] A61K 31-42; A61K 31-175

FULL TEXT: 4434 lines

23/8/26 (Item 6 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02964042

CONJUGATES OF DITHIOCARBAMATES WITH PHARMACOLOGICALLY ACTIVE AGENTS AND
USES THEREFORE

[Antiinflammatory agents; side effect reduction]

U.S. CLASS: 514-423 cross ref: 514-514; 548-564; 548-573; 558-235

INTL CLASS: [6] C07D 207-04; C07D 207-30; A61K 31-27; A61K 31-40

FULL TEXT: 1695 lines

23/8/27 (Item 7 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02748173

2,9-DIAMINO- AND 2-AMINO-8-CARBAMOYL-4-HYDROXY-ALKANOIC ACID AMIDE
DERIVATIVES

[Hypotensive agents]

U.S. CLASS: 514-211 cross ref: 514-213; 514-221; 514-224.2; 514-230.5;
514-249; 514-259; 514-311; 514-315; 514-349; 540-593; 544-52;
544-105; 544-253; 544-283; 544-355; 546-168; 546-175; 546-245;
546-246; 548-309.4; 548-309.7; 548-491; 548-493

INTL CLASS: [6] A61K 31-54; A61K 31-535; C07D 413-02; C07D 411-02

FULL TEXT: 8310 lines

23/8/28 (Item 8 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02727327

TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS
CANCERS

[Administering to the patient an effective amount of isoxazole amide
derivative and cyano, hydroxy, aromatic amide derivative]

U.S. CLASS: 514-380 cross ref: 514-379

INTL CLASS: [6] A61K 31-42

FULL TEXT: 4441 lines

23/8/29 (Item 9 from file: 654)

DIALOG(R)File 654:(c) format only 2001 The Dialog Corp. All rts. reserv.

02624996

COMPOSITIONS AND METHODS FOR ENHANCED DRUG DELIVERY

[Iontophoresis]

U.S. CLASS: 424-449 cross ref: 514-1; 514-2; 514-26; 514-169; 514-183;
514-553; 514-556; 604-20

INTL CLASS: [6] A61K 9-70 A61K 31-00

FULL TEXT: 5232 lines

?